IFM Investors Pty Ltd Grows Stock Holdings in Johnson & Johnson (NYSE:JNJ)

IFM Investors Pty Ltd lifted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 7.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 486,648 shares of the company's stock after acquiring an additional 32,749 shares during the period. Johnson & Johnson makes up approximately 0.8% of IFM Investors Pty Ltd's portfolio, making the stock its 20th largest position. IFM Investors Pty Ltd's holdings in Johnson & Johnson were worth $78,866,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. GF Fund Management CO. LTD. boosted its holdings in Johnson & Johnson by 5.1% in the first quarter. GF Fund Management CO. LTD. now owns 63,449 shares of the company's stock worth $10,522,000 after purchasing an additional 3,101 shares during the last quarter. OneDigital Investment Advisors LLC boosted its stake in shares of Johnson & Johnson by 1.1% during the 1st quarter. OneDigital Investment Advisors LLC now owns 87,424 shares of the company's stock worth $14,498,000 after acquiring an additional 916 shares during the last quarter. 44 Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 1.4% during the 1st quarter. 44 Wealth Management LLC now owns 18,269 shares of the company's stock worth $3,030,000 after acquiring an additional 260 shares during the last quarter. Avantax Planning Partners Inc. raised its position in shares of Johnson & Johnson by 4.0% during the 1st quarter. Avantax Planning Partners Inc. now owns 44,955 shares of the company's stock valued at $7,455,000 after purchasing an additional 1,717 shares during the period. Finally, Silver Oak Securities Incorporated increased its holdings in Johnson & Johnson by 13.8% in the 1st quarter. Silver Oak Securities Incorporated now owns 8,637 shares of the company's stock valued at $1,414,000 after acquiring an additional 1,045 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Barclays lowered their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $170.88.

Johnson & Johnson Price Performance

JNJ stock traded down $0.04 during mid-day trading on Wednesday, hitting $155.75. 2,794,086 shares of the stock were exchanged, compared to its average volume of 8,036,905. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The business has a fifty day moving average price of $153.67 and a 200 day moving average price of $154.25. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a market capitalization of $374.75 billion, a price-to-earnings ratio of 17.32, a PEG ratio of 2.35 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.34%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.